Dr.Kaviya.K.J II yr MD Prof. Dr. R. Subramaniya Bharathiyar ;Professor and H.O.D

1. COMPARISON OF EFFECT OF ONDANSETRON Vs PALONOSETRONIN PREVENTION OF POST OP NAUSEA AND VOMITING FOLLOWINGENT SURGERIES Dr.Kaviya.K.J II yr MD Prof. Dr. R. Subramaniya Bharathiyar ;Professor and H.O.D Prof. Dr. R. Lakshmi, Associate Professor Prof Dr.Ponnambala Namasivayam,Associate Professor Dr.Carolin von mullai Assistant professor Dept of anesthesiology SMC. Dr.MGR University 2010

2. BACKGROUND • Postoperative nausea and vomiting (PONV) “big little problem”is a frequent complication of surgery, which can lead to subject discomfort and dissatisfaction as well as considerable subsequent medical and economic consequences . • nausea and vomiting within the 24–72 h period occur with an incidence of approximately 30% and 5% respectively. • Gupta et al. found a 32.6% incidence of PDNV.15 In the high-risk patients receiving placebo the incidence of PDNV was approximately 60% in the studies by Kovac et al

3. Schematic representation of the factors influencing nausea and vomiting

4. Risk Factors:Patient Specific Simplified Scoring System • Female • Nonsmoking history • Hx of motion sickness or PONV • Use of postoperative opioids Incidence of PONV Apfel CC et al. Anesthesiology 1999;91:693-700.

5. Chemoreceptor Trigger Zone and Emetic Center Antagonist Promethazine 5-HT3 RAs Droperidol Atropine NK-1 RA Agonist Dopamine (D2) 5-HT3 Muscarinic Histamine Substance P Receptor Site • Nitrogen mustard • Cisplatin • Digoxin glycoside • Opioid, analgesics • Vestibular portion • of 8th nerve • N2O • GI tract distension • Higher centers (vision, taste) • Pharynx Chemoreceptor Trigger Zone (CTZ) Area Postrema Mediastinum Parvicellular Reticular Formation Emetic Center ? Vagus

6. Palonosetron second generation 5-HT3 RA • a unique chemical structure. T1/2 40 hrs • Exhibits high binding affinity. • allosteric binding and positive cooperativity, • induces receptor internalisation • Palonosetron 0.075 mg IV is approved by FDA (PONV) for up to 24 hours following surgery. SIDE EFFECTS: • headache (3%), • constipation (2%) • prolongation of the QTc interval (5%)

7. Rojas et al. described the unique pharmacology of palonosetron compared with other 5-HT3 receptor antagonists, • Tang et al. demonstrated a dose response for palonosetron up to 30 μg/kg, with 1 μg/kg being the lowest effective dose in the first 24 h for PONV • Kovac et al.7 and Candiotti et al. At the highest dose studied (0.075 mg), the incidence of vomiting or need for antiemetic treatment was reduced during the first 24 h after surgery by approximately 20%-30% &found a marked reduction in incidence and severity within the first 24 h . • Kovac et al. demonstrated continued efficacy compared with placebo for 24 to 72 h.

8. AIM OF THE STUDY The purpose of this study is to investigate Iv palonosetron versus Iv ondansetron medication for the prevention of nausea and vomiting through 72 hours postoperatively in patients undergoing ENT procedures requiring general anesthesia. • Primary Outcome Measures: • proportion of patients with no emetic episodes in the Time Frame: 0-72 hours post-operatively • Secondary Outcome Measures: • Proportion of patients with no emetic episodes in different time periods :Time Frame: 0-6 hours, • 6-24 hours, • 24-72 hours, • Severity of nausea in different time periods • Time Frame: 0-6 hours, • 6-24 hours, • 24-72 hours,

9. Study design • Interventional • Single blind • Prospective • Randomised • Non placebo

10. PATIENTS AND METHODS: • Institutional Ethics Committee approval was obtained • Informed written consent was obtained • 60 patients belonging to ASA PS 1 &2 undergoing ENT surgeries under general anesthesia were chosen and randomly divided into 2 groups each n=30 • Group O received Inj ondansetron 75mcg/kg upto 8mg • Group P received Inj Palonosetron 1.5mcg/kg upto 0.075mg • 30 minutes before start of surgery

11. MAIN INCLUSION CRITERIA • Male or female patient aged more than 5 years up to 60 years. • Inpatient scheduled to undergo surgical procedures requiring general endotracheal anesthesia for ear, nose and throat surgery; • American Society of Anesthesiologists (ASA) physical status I, II • Patient scheduled to be hospitalized for at least 72 hours after wake up of surgery

12. MAIN EXCLUSION CRITERIA • History of gastro-esophageal reflux. • Patient scheduled to undergo emergency surgery. • Patient scheduled to receive propofol during the maintenance phase of anesthesia. • Patient with vomiting from any organic cause. • Any drug with a potential anti-emetic effect within 24 hours prior to the administration of anesthesia. • Any vomiting, retching, or nausea in the 24 hours preceding the administration of anesthesia.

13. Materials • IV cannulae • Monitors • Drugs for general anaesthesia • Drug O Ondansetron 4mg • Drug P Palonosetron 0.075 mg

14. METHODS • Premedication: Inj. Glycopyrolate 0.004 mg/kg iv, • Inj. Midazolam 0.02mg /kg iv, • Inj. Fentanyl 2 mcg/kg iv. • Anaesthesia was induced with • Inj. Thiopentone 5mg/kg iv and • Inj succinylcholine 2mg /kg iv • Intubated with appropriate sized ETT • placement confirmed .

15. METHODS • Anaesthesia was maintained with • N2O: O2 70:30%, • Isoflurane 1% with controlled ventilation • Muscle relaxant Inj Atracurium loading dose of 0.5mg/kg followed by a maintanence dose of 0.1mg/kg was used • After adequate spontaneous respiratory effect reversed with Inj neostigmine 50mcg/kg with Inj glycopyrrolate 40mcg/kg. • During maintenance of anesthesia • Heart rate, Mean arterial blood pressure, ECG • Spo2, respiratory rate, end-tidal CO2 concentration,

16. Post operative: Data collected over 72 hrs post op. • No of emetic episodes recorded and time at which it occurred. • Emetic episode is defined as single vomit or retch or a combination • Complete response: No emetic episode • Major response :one emetic episode • Treatment failure: 2 or more episode or the receipt of an rescue anti emetic • Data recorded & results were statistically evaluated

17. ONDANSETRON MEAN AGE 26+/-4 [5yrs-50yr] SEX M/F 15/15 RESULTS DEMOGRAPHIC DISTRIBUTION: PALONOSETRON MEAN AGE:24+/-5 [5Yrs-52] SEX:M/F 14/16

18. COMPLETE RESPONSE

19. NAUSEA

20. HEADACHE

21. CONCLUSIONS • Emesis and nausea female>male • Emesis early 0-12 hrs comparable • Emesis delayed 12-72 hrs palonosetron superior • Palonosetron superior in controlling nausea • Headache symptoms comparable

22. PROFORMA • NAME : AGE/SEX: IP NO: • WEIGHT: ASA I II • DIAGNOSIS: SURGERY PLANNED: • PREMED: TIME OF DRUG ADMINISTERED: • TECHNIQUE OF ANESTHESIA: • CONDITION AT THE END OF SURGERY: • PONV FIRST 2 HRS 2-12 HRS 12-24 24-72 • NO OF EMETIC EPISODES NAUSEA Mild moderate severe

23. REFERENCES • Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology.1999;91(3):693–700. • Management of PONV focus on palonosetron Neil muchatuta michael peach 2008 • K. A. Candiotti, A. L. Kovac, T. I. Melson, G. Clerici, T. Joo Gan, and The Palonosetron 04-06 Study GroupA Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Three Different Doses of Palonosetron Versus Placebo for Preventing Postoperative Nausea and VomitingAnesth. Analg., August 1, 2008; 107(2): 445 - 451 • Palonosetron Hcl in the prevention of PONV Jane wallenborn and Peter crank dept of anesthesiology University of leizpig.Germany • Gralla R, Lichinitser M, Van der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570–7 • Stoltz R, Cyong J-C, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 2004;44:520–31

24. THANK U